Case Series
Recently Published Documents


TOTAL DOCUMENTS

33057
(FIVE YEARS 21811)

H-INDEX

117
(FIVE YEARS 54)

2021 ◽  
Vol 73 ◽  
pp. S84
Author(s):  
Sumit Vipin Kumar ◽  
Girish Ramkrishna Sabnis ◽  
Hetan Chandrakant Shah ◽  
Charan Pandurang Lanjewar

2021 ◽  
Vol 73 ◽  
pp. S20-S21
Author(s):  
Radhapriya Yalamanchi ◽  
Refai Showkathali ◽  
Muthukumaran C. Sivaprakasam ◽  
Raja Vijendra Reddy Janke ◽  
Krishnaswamy Chandrasekharan

2021 ◽  
Vol 28 (6) ◽  
pp. 5019-5024
Author(s):  
Scott J. Dawsey ◽  
Moshe C. Ornstein

There have been significant advances in the treatment of metastatic renal cell carcinoma (mRCC), with immunotherapy (IO)-based combinations as the standard-of-care treatment in the front-line setting. IO in this setting is paired with another IO agent or with a vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitor (TKI). One IO/IO combination and four IO/TKI combinations are currently approved. However, the role of the salvage IO in patients with disease progression on TKI monotherapy is uncertain. Here, we present a case series of five patients who were on single-agent TKI therapy for treatment-refractory mRCC and upon disease progression had an IO agent added to their TKI. The median duration of TKI monotherapy was 11.2 months (range, 1.7–31.1 months), and the median duration of response after the addition of IO was 4 months (range, 2.8–10.5 months). Although IO salvage therapy has a plausible rationale, this case series did not show a clear benefit to this approach. Further clinical trials are needed to determine the clinical utility of IO salvage therapy in mRCC.


Author(s):  
Antoine Devalckeneer ◽  
Rabih Aboukais ◽  
Maxime Faisant ◽  
Philippe Bourgeois ◽  
Vannod-Michel Quentin ◽  
...  

2021 ◽  
Vol 25 (4) ◽  
pp. 462-471
Author(s):  
Valentine Martin ◽  
Emilie Gregoire ◽  
Sophie Chopinet ◽  
Olivier Scatton ◽  
Rémi Dubois ◽  
...  

2021 ◽  
Author(s):  
Shimeng Liang ◽  
Weibing Leng ◽  
Dan Jiang ◽  
Ming Liu ◽  
Dan Cao ◽  
...  

Abstract Background Immunotherapy has revolutionized the treatment of malignant tumors. However, limited clinical data are available to report the efficacy of immune checkpoint inhibitors (ICIs) on Epstein-Barr virus-associated gastric carcinoma. Methods In this study, we report a case series of five patients with metastatic Epstein-Barr virus-associated gastric carcinoma who were treated with ICIs and to perform a pooled analysis of published cases to investigate the efficacy of ICIs in Epstein-Barr virus-associated gastric carcinoma patients. Results Between 2018 and 2020, five metastatic gastric cancer patients with EBV positivity who received PD-1 antibodies treatment were included in the analysis at the authors’ institution. Furthermore, we performed a pooled analysis of the contemporary literature. In our case series, two patients experienced partial response (PR); one patient achieved complete response (CR), whereas two patients had progression disease (PD), resulting an ORR of 60%. In the pooled analysis of all 36 patients, ORR was 48.6% (17/35). For the first line and later lines, it was 75% (3/4) and 45.2% (14/31) respectively. The ORR was 46.7% (14/30) for ICIs monotherapy and improved to 60% (3/5) by combination with chemotherapy. Conclusions These results demonstrated that an EBV-positive status was a reliable biomarker for immunotherapy in metastatic gastric cancer, especially for monotherapy. Immunotherapy combined with chemotherapy may be a better strategy, warranting further large-scale clinical trials for validation.


2021 ◽  
Vol 9 (12) ◽  
pp. 2471
Author(s):  
Eve Ronin ◽  
Christian Derancourt ◽  
André Cabié ◽  
Karine Marion-Sanchez

Achromobacter species are isolated from rare but severe healthcare-associated infections, including surgical site infections. They are considered to preferentially infect immunocompromised patients but so far with limited evidence. We conducted a systematic review on Achromobacter spp. surgical site infections (SSIs) to determine if such infections were indeed more commonly associated with immunocompromised patients. The secondary objective was to describe the characteristics of infected patients. Eligible articles had to be published before 30 September 2020 and to report Achromobacter spp. SSIs across all surgical specialties excluding ophthalmology. Analyses were performed on individual data without meta-analysis. Cases were divided into 2 subgroups: one group which had either prosthesis or implant and the other group which did not. A first selection led to a review of 94 articles, of which 37 were analyzed. All were case reports or case series and corresponded to 49 infected patients. Most of the patients were under 65 years of age and had undergone a heart or digestive surgery followed by deep infection with no co-infecting pathogens. Nine out of the 49 cases were immunocompromised, with similar distribution between the two subgroups (16.6% and 20%, respectively). This review suggests that Achromobacter spp. SSIs do not preferentially target immunocompromised patients.


2021 ◽  
Vol 41 (12) ◽  
pp. 6225-6230
Author(s):  
HIROSHI AOKI ◽  
NAOKI MATSUMOTO ◽  
HIROSHI TAKAHASHI ◽  
MASAYUKI HONDA ◽  
TOMOHIRO KANEKO ◽  
...  

Dermatology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Khalifa E. Sharquie ◽  
Muhsin A. Al-Dhalimi ◽  
Ahmed Abdulhussein Kawen ◽  
Samer A. Dhaher

<b><i>Background:</i></b> Burn hemangioma, also known as scalded pyogenic granuloma, is considered a variant of pyogenic granuloma, but unlike the classic type it presents with rapid progression. Most patients are infants and young children with a history of burns caused by liquids. <b><i>Objective:</i></b> The present study aims to present all patients with burn hemangiomas treated at our institutions with a full clinical and histopathological assessment. <b><i>Patients and Methods:</i></b> This case series includes 34 cases that were treated during the period from 2016 to 2021. <b><i>Results:</i></b> A total of 34 patients (16 female/18 male, mean age of 17.6 years) were included. Two age groups presented: infants and children (<i>n</i> = 22, age range 0.5–8 years, 10 female/12 male), and adults (<i>n</i> = 11, age range 25–44 years, 6 female/6 male). Lesions appeared 1–2 weeks following predominantly second-degree burns, and multiple lesions predominated in infants and children. The lesions evolved to large lesions within weeks, and these appeared to be either static or involute. The histopathology was compatible with hemangioma, rather than pyogenic granuloma. <b><i>Conclusion:</i></b> Burn hemangioma should be considered a new variant of hemangioma rather than a type of pyogenic granuloma that follows second-degree burns. They have many similarities with infantile hemangioma, both clinically and histopathologically.


Sign in / Sign up

Export Citation Format

Share Document